- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02371863
Normal Values in Stress Echocardiographic Parameters in Patients After Successful Mitral Valve Repair for Organic MR (SEP)
SEP-study; The Assessment of Normal Values in Stress Echocardiographic Parameters in Patients After Successful Mitral Valve Repair for Organic Mitral Valve Regurgitation
Surgical treatment is the only approach with potentially defined clinical success for organic mitral valve (MV) regurgitation. Recurrent or persistent complaints after initial successful MV repair is a clinical challenge in current practice. Especially when echo parameters at rest are within or near normal ranges and patients presenting disproportionately symptomatic in relation to the observed results. However, while MV regurgitation is a hemodynamic disease, currently used 2-dimensional (2D) transthoracic echocardiography (TTE) at rest lacks information about hemodynamic changes. Physical stress echocardiography is a promising technique to complement nowadays rest TTE in order to improve interpretation of hemodynamic changes. However, normal values for exercise echo are lacking in this postoperative patients cohort. A prospective, observational trial to determine normal values in stress echocardiographic parameters in asymptomatic patients after successful MV repair for organic MV regurgitation, is therefore highly needed.
Purpose of the SEP- study is to determine normal values in stress echocardiographic parameters in asymptomatic patients at least 6 months after successful MV repair for organic MV regurgitation. These normal values for stress echo are of utmost importance to correctly and accurate interpret stress echo results during postoperative follow-up and to improve clinical decision making in patients post MV repair.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- University Medical Center Utrecht (UMC Utrecht)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥18 years;
- Male or female from all ethnicities;
- At least 6 months post successful, isolated MV repair. S
- Asymptomatic
Exclusion Criteria:
- Pulmonary hypertension >50 mmHg at rest;
- Atrial fibrillation (AF) at time of study related stress echo test;
- Known contraindication or incapability to perform peak exercise or inability to perform physical stress testing;
- LVEF <45%;
- NYHA class II and more.
- Other heart valve disease of more than mild severity;
- Concomitant surgery during MV repair, e.g. MAZE, TVP procedure;
- Prior heart valve surgery;
- Congenital heart disease;
- Disabling comorbidity, e.g. chronic obstructive pulmonary disease (COPD);
- Unable to provide informed consent
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Echocardiographic parameter: Peak mitral valve mean gradient (mmHg)
Time Frame: at least 6 months after successful MV repair
|
Echocardiographic measured mitral valve mean gradient at peak physical exercise
|
at least 6 months after successful MV repair
|
|
Echocardiographic parameter: Peak systolic pulmonary artery pressure (sPAP, mmHg)
Time Frame: at least 6 months after successful MV repair
|
Echocardiographic measured sPAP at peak physical exercise
|
at least 6 months after successful MV repair
|
|
Echocardiographic parameter: Increase in mitral valve regurgitation grade (grade 0-4, according to ESC guidelines)
Time Frame: at least 6 months after successful MV repair
|
Echocardiographic measured increase in mitral valve regurgitation at peak physical exercise during physical stress echo, compared to rest echo.
Grading of mitral regurgitation will be performed according to the ESC guidelines.
|
at least 6 months after successful MV repair
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Echocardiographic parameter: Left ventricular function (LVF, quality description)
Time Frame: at least 6 months after successful MV repair
|
Echocardiographic measured LVF quality at rest and peak physical exercise
|
at least 6 months after successful MV repair
|
|
Echocardiographic parameter: Mitral valve area (MVA, cm2)
Time Frame: at least 6 months after successful MV repair
|
Echocardiographic measured MVA at rest and peak physical exercise
|
at least 6 months after successful MV repair
|
|
Echocardiographic parameter: Peak mitral valve peak gradient (mmHg)
Time Frame: at least 6 months after successful MV repair
|
Echocardiographic measured mitral valve peak gradient at peak physical exercise
|
at least 6 months after successful MV repair
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven AJ Chamuleau, MD, PhD, UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL39865.041.14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Valve Diseases
-
IRCCS Policlinico S. DonatoRecruitingMitral Valve Prolapse | Myxomatous Mitral Valve DegenerationItaly
-
National University of Ireland, Galway, IrelandNot yet recruitingSurgical Valve Replacement | AORTIC VALVE DISEASES | Valve Disease, Aortic | Valve-in-valve ProceduresIreland
-
Michael MorontRecruitingValve Disease, Heart | Valve Replacement | Valve Heart Stenosis | Valve Regurgitation, MitralUnited States
-
Centro Cardiologico MonzinoAzienda Ospedaliero-Universitaria di Parma; Policlinico SS Annunziata di ChietiActive, not recruitingMitral Regurgitation | Mitral Valve ProlapseItaly
-
Meril Life Sciences Pvt. Ltd.Not yet recruitingAortic Valve Disease, Mitral Valve Disease, Prosthetic Heart Valve Dysfunction | Valvular Heart Disease Requiring Surgical Aortic or Mitral Valve Replacement
-
National Heart, Lung, and Blood Institute (NHLBI)WithdrawnHeart Failure | Aortic Valve Stenosis | Mitral Valve Regurgitation | Heart Valve Disease | Tricuspid Valve RegurgitationUnited States
-
TRiCaresRecruitingCardiovascular Diseases | Heart Valve Disease | Tricuspid Valve RegurgitationBelgium, Germany
-
University of SalernoActive, not recruitingMitral Valve Failure | AORTIC VALVE DISEASESItaly
-
Boston Children's HospitalRecruitingValve Disease, Heart | Valve Heart Disease | Valve Disease, AorticUnited States
-
UMC UtrechtLeiden University Medical Center; The Interuniversity Cardiology Institute... and other collaboratorsTerminatedMitral Valve Insufficiency | Diseases of Mitral Valve | Heart; Disease, Mitral(Valve)Netherlands